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HIV/AIDS treatment failure and associated
factors in Ethiopia: meta-analysis
Aklilu Endalamaw1* , Mengistu Mekonnen2, Demeke Geremew3, Fikadu Ambaw Yehualashet4, Hiwot Tesera5 and
Tesfa Dejenie Habtewold6
Abstract
Background: The national burden of human immunodeficiency virus treatment failure and associated factors in the
Ethiopian context is required to provide evidence towards a renewed ambitious future goal.
Methods: We accessed Ethiopian Universities’ online repository library, Google Scholar, PubMed, Web of Science, and
Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by
using Egger’s regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects
model. We employed the sensitivity analysis to see the presence of outlier result in the included studies.
Results: The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6–20.1%).
Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95%
confidence interval: 6.9–13.6%), 5.6% (95% confidence interval: 2.9–8.3%), and 6.3% (95% confidence interval: 4.6–8.0%),
respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3–
2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2–2.4), and poor adherence to highly
active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3–11.8) on HIV treatment failure were estimated.
Conclusions: Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced
clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the
contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention
programs need to address the specified contributing factors of human immunodeficiency virus treatment failure.
Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus
treatment adherence.
Protocol registration: It has been registered in the PROSPERO database with a registration number of
CRD42018100254.
Keywords: HAART, HIV, Failure, Treatment, Ethiopia
Background
Globally, there were approximately 37.9 million Human
Immunodeficiency Virus (HIV) infected people and
around 770,000 people died from AIDS-related illnesses
worldwide in 2018. In this year, there were 20.6 million
people with HIV in eastern and southern Africa, and 5.0
million in western and central Africa [1]. In Ethiopia,
690,000 people were living with HIV in 2018 [2].
In 2018, 23.3 million people with HIV were accessing
antiretroviral therapy (ART) worldwide [1]. In the same
year, 65% of people living with HIV were on treatment
in Ethiopia [2]. A review of the HIV situation in Addis
Ababa Ethiopia revealed that weak monitoring of the
quality of interventions, limited linkage of HIV-positive
clients, lost to follow-up, financial shortage, limited
man-power, and gaps in the use of program data were
the challenges of HIV/AIDS treatment [3].
The risk of death due to HIV has been decreased after
the era of highly active antiretroviral therapy (HAART)
[4]. Evidence has shown that an individual on HAART
with an undetectable viral load, absence of an advanced
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clinical finding, and high CD4 count are less likely to
transmit HIV to another person [5, 6]. However, the risk
of HIV transmission is high due to treatment failure.
Treatment failure can be a virological, immunological, or
clinical failure [7]. Virological failure is a plasma viral load
above 1000 copies/ ml based on two consecutive viral load
measurements after 3months with adherence support [7].
Immunological failure is when the CD4 count falls to the
baseline (or below) or persistent CD4 levels below 100
cells/mm3 for adult and adolescent or below 200 cells/
mm3 in younger than 5 years. Clinical failure is defined as
the occurrence or recurrence of advanced WHO clinical
stage after 6months of therapy [7].
Globally, UNAIDS planned to have 90% of people on
HAART are virally suppressed by 2030 and as a result,
HIV treatment failure would be prevented [8]. Despite this
ambitious goal, as of a systematic analysis of national HIV
treatment cascades of 69 countries by 2016, viral suppres-
sion was between 7% in China and 68% in Switzerland [9].
It can be prevented through the implementation of glo-
bally recommended strategies. For instance, improving
HAART adherence, taking medication based on the ap-
propriate prescription, prevent drug-drug interaction, in-
creasing knowledge and attitudes of patients towards
HAART, timely initiation of HAART, prevention and con-
trol of opportunistic infections, and implementation of ef-
fective food and nutrition policy.
A higher viral load may lead to HIV treatment failure,
which is becoming a threat of different African countries,
like in Burkina Faso (6.4%) [10], Ghana (15.7%) [11], and
Tanzania (14.9%) [12]. In Ethiopia, virological, immuno-
logical, and clinical failure is found in the range between
1.3% [13] to 11.5% [14], 2.1% [15] to 21% [16], and 3.1%
[17] to 12.3% [18], respectively.
With these variations of reports, there is no pooled rep-
resentative national data in Ethiopia. In order to provide
evidence towards a renewed ambitious future goal, it is
now critical to reflect the pooled burden of HIV treatment
failure in the Ethiopian context. The objective of this study
was first, to estimate the national burden of HIV treatment
failure and secondly, to review contextual factors of HIV
treatment failure using globally accepted key performance
indicators as a framework. Thus, this information will be
helpful for healthcare professionals and further helps to en-
able the country to sustain successes and improve weak-
nesses towards the goal of ending AIDS strategy.
Methods
Reporting
It is reported based on the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) guide-
line [19] (supplementary file-research checklist). Its
protocol is registered in the Prospero database with a
registration number of CRD42018100254.
Search strategy
PubMed, Web of Science, Scopus, and Google Scholar da-
tabases were used to get the research articles. The search
strategy made in PubMed was: [(“Human Immunodefi-
ciency virus”[MeSH Terms] OR HIV OR AIDS OR “Ac-
quired Immunodeficiency syndrome” AND (“antiretroviral
therapy”[MeSH Terms] OR “highly antiretroviral therapy”
OR HAART OR ART OR “ARV Therapy” OR “antiretro-
viral therapy”) AND (outcome OR “treatment failure” OR
failure OR “virological failure” OR “immunological failure”
OR “Clinical failure”) AND (Ethiopia)]. The search done in
PubMed through search terms was 03/10/2018. In addition,
Ethiopian Universities’ (University of Gondar and Addis
Ababa University) online repository library were searched.
Endnote 7 reference manager software was used to manage
duplicated references and for citation in the text.
Inclusion and exclusion criteria
Those articles included in this meta-analysis were: [1] co-
hort, case-control, and cross-sectional studies, [2] studies
that reported the prevalence and/ or AOR (adjusted odds
ratio) of associated factors of overall HAART treatment,
immunological, clinical, and virological failure, [3] studies
conducted in Ethiopia, and [4] studies published in English.
Studies without full-text access, qualitative studies, and
conference proceeding without full-text reports were
excluded.
Outcome measurement
According to WHO [7], HIV treatment failure could be
a clinical, immunological, and virological failure.
The prevalence of failure was ascertained by dividing
the participants with the outcome of interests to the
overall study participants multiplied by 100.
Quality assessment
Two authors assessed the quality of the articles based on
the Newcastle-Ottawa Scale quality assessment tool for
cross-sectional, case-control, and cohort studies [20]. The
criteria for cross-sectional studies have three sections, in
which the first section focused on selection and graded by
four stars, the second section dedicated with the compar-
ability of the study and graded by two stars, and the third
section emphasized on the outcome and graded by three
stars. The criteria for case-control studies were: 1) selec-
tion evaluated by four stars, 2) comparability assessed by
two stars, and 3) exposure graded by four stars. The cri-
teria for cohort studies were: 1) selection graded by six
stars, 2) comparability graded by two stars, and 3) out-
come graded by five stars. Whenever disagreement hap-
pened between the two quality assessors, the procedure
would be repeated and further solved with the involve-
ment of the third reviewer. Cross-sectional, case-control,
and cohort studies scored 6 and/or above, 7 and/or above,
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and 9 and/or above quality assessment criteria were in-
cluded respectively.
Data extraction process
Two authors extracted the required data. The first author
and year of publication, sample size, an outcome of inter-
est, study design, study population, the geographical loca-
tion of the study, fund, and response rate were collected.
Data synthesis and statistical analysis
STATA 14 (Stata Corp, College Station, TX, USA) statis-
tical software was used for meta-analysis. Publication bias
assessed by the funnel plot and more objectively by
Egger’s regression test. I-squared statistics was used to
check the heterogeneity of the studies. The DerSimonian-
Laird random-effects model was employed to estimate the
overall prevalence. Subgroup analysis based on the geo-
graphical location of the study, type of treatment failure,
study population by age, and study design was conducted
to see the variation in outcomes. The sensitivity analysis
was also employed to see whether the outlier result found
in the included studies.
Results
Search results
A total of 873 articles were found from PubMed (n = 187),
Google Scholar (n = 134), Web of Science (n = 21), Scopus
(n = 13), and Ethiopian Universities’ online repository
library (University of Gondar and Addis Ababa University)
(n = 33). A total of 331 articles have remained after dupli-
cate studies were removed. Then, 302 articles were re-
moved based on the unmatched title and abstracts.
Finally, 18 articles were included (Fig. 1).
Characteristics of studies
Studies found through databases search were done between
2005 and 2016. Eight of the studies were conducted in the
Amhara region, whereas five in Addis Ababa [13, 21–24],
three in Oromia [18, 25, 26], one in Tigray [14], and one in
SNNPR [27]. Three studies were done by case-control
study design [24, 28, 29], four studies by cross-sectional
[14, 30–32], and eleven by cohort study design [13, 15–18,
21–23, 25–27]. Ten studies were done on adult population
[13, 16, 17, 21, 23–25, 28, 29, 32], six on children [15, 18,
22, 26, 27, 31], and two on all age group [14, 30] (Table 1).
Publication bias
The funnel plot for HIV treatment failure is shown below
(Fig. 2). Egger’s regression test of the p-value for overall
HIV treatment failure is 0.226.
Meta-analysis
HIV treatment failure based on the definition of HAART
failure
A total of 4738 participants in nine studies were used to
estimate the pooled prevalence of HIV treatment failure
Fig. 1 PRISMA flow-chart diagram describing the selection of studies
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based on the definition of HAART failure. The pooled
prevalence of HIV treatment failure was 15.9% (95% CI:
11.6–20.1%) (Fig. 3).
Immunological and Virological definition of HIV treatment failure
A total of 5899 study participants in 13 studies were involved
to determine HIV treatment failure based on the immuno-
logical definition. Of which, 10.2% (95% CI: 6.9–13.6%) de-
veloped immunological failure. Regarding virological failure,
the pooled prevalence from six studies with a total of 2406
participants was 5.6% (95% CI: 2.9–8.3%) (Fig. 4).
Clinical definition of HIV treatment failure
A total of 4497 study participants in 9 studies were
found to estimate the clinical failure, in which the
pooled prevalence was 6.3% (95% CI: 4.6–8.0%) (Fig. 5).
Subgroup analysis
Subgroup analysis was employed based on region, age of
the study participants, and study design. Lower preva-
lence of HIV treatment failure based on the definition of
HAART, immunological, and virological failure was
13.7%in Amhara, 6.5% in Tigray, and 1.5% in Addis
Ababa, respectively (Table 2).
Sensitivity analysis
In the sensitivity analysis, the overall HIV treatment fail-
ure based on the definition of HAART failure was ob-
served high (17.3%) and low (15.2%) when Ayalew MB
et al 2016 and Sisay C et al/2017 was omitted respect-
ively. The minimum pooled prevalence of HIV treatment
failure based on immunological definition (9.3%), viro-
logical definition (4.4%), and clinical definition (5.5%)
Table 1 Characteristic of included studies in systematic review and meta-analysis
First Author/Year Study
period













Adult 293 100% Not reported
Bokretsion BG et al./
2017 [23]
2016 Amhara Cross-sectional All age
group
421 100% Bahirdar University and Ethiopian public
health institute




children 269 86.8% Not reported




children 225 100% Not reported






Adult 525 100% Not reported








children 1186 100% Not reported






Adult 340 100% University of Gondar, Ethiopia






children 824 81.9% University of Gondar, Ethiopia






Adult 356 100% University of Gondar,Ethiopia




Tigray Cross-sectional All age
group
260 100% Mekelle Univesity, Ethiopia






Adult 509 100% University of Gondar,Ethiopia






Adult 265 100% Danish International Development Agency
(DANIDA)




SNNPR cohort children 628 100% Hawassa University, Ethiopia






children 96 100% Jimma University, Ethiopia






Adult 595 100% Ethiopian public health institute
Babo YD et al./2017
[26]
2014 Amhara Case-control Adult 304 100% USAID
Bayu B et al./2017 [27] 2015 Amhara Case-control Adult 306 100% Not reported




Case-control Adult 309 100% Jimma University, Ethiopia
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Fig. 2 Funnel plot, in which the vertical line indicates the effect size whereas the diagonal line indicates the precision of individual studies with
95% confidence limit
Fig. 3 Forest plot of the prevalence of HAART failure in Ethiopia and its 95%CI, the midpoint of each line illustrates the prevalence rate estimated
in each study. The diamond shows pooled prevalence
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Fig. 4 Forest plot of the prevalence of immunological and virological failure in Ethiopia and its 95%CI, the midpoint of each line illustrates the
prevalence rate estimated in each study. The diamond shows pooled prevalence
Fig. 5 Forest plot of the prevalence of clinical failure in Ethiopia and its 95%CI, the midpoint of each line illustrates the prevalence rate estimated
in each study. The diamond shows pooled prevalence
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when Yayehirad AM et al/2013, Hailu GG et al /2015,
and Yassin S /2016 omitted, respectively. And the max-
imum pooled prevalence of HIV treatment failure based
on immunological definition (10.8%) and virological fail-
ure (6.5%) Ayalew MB et al/2016 and Yimer YT/2015
was dropped from the analysis, respectively (Table 3).
Associated factors of HIV treatment failure
HIV treatment failure is attributed to socio-demographic,
clinical, drug, and health system-related factors.
Socio-demographic factors
Based on a single study report, children’s age between 6
and 9 years (AOR = 0.26; 95% CI: 0.09–0.72) was protect-
ive towards HIV treatment failure as compared to 10–15
years old children [18]. Another study showed children
less than 3 years old were high risk (AHR = 1.85; 95% CI:
1.24–2.76) for HIV treatment failure as compared to
5–15 years old children [22].
One study which was done on the adult population
[29] showed that those aged < 35 years were high risk
Table 2 Subgroup analysis of the prevalence (p) of HIV treatment failure based on overall HAART, immunological, virological, and
clinical definition by region, age, and study design in Ethiopia
Subgroup analysis Overall HAART failure P (95%CI) Immunological failure P (95%CI) Virological failure P (95%CI) Clinical failure P (95% CI)
By Region
Amhara 13.7 (7.3–20.2) 9.3 (3.3–15.2) 7.1 (0.03–14.1) 5.7 (2.6–8.9)
Oromia 18.8 (16.8–20.8) 8.9 (4.2–13.6) 5.3 (3.8–6.8) 8.8 (1.9–15.7)
Addis Ababa 18.4 (13.6–23.3) 13.2 (7.9–18.4) 1.5 (1.0–2.0) 5.5 (4.4–6.6)
Tigray __ 6.5 (4.9–8.2) 11.5 (9.6–13.4) __
By age of participants
All age group 20.0 (18.4–21.6) 11.2 (2.0–20.4) 11.0 (9.9–12.2) 11.2 (9.7–12.7)
Adult 16.0 (7.4–24.7) 12.9 (7.6–18.3) 2.8 (1.5–4.1) 4.6 (2.9–6.3)
Children 14.6 (9.7–19.6) 6.4 (3.6–9.3) __ 6.4 (4.2–8.5)
By Study design
Cross-sectional 14.1 (3.0–25.2) 8.1 (2.7–13.5) 8.5 (3.2–13.9) 7.2 (0.8–15.8)
Cohort 16.8 (12.2–21.37) 11.2 (6.8–15.6) 2.6 (1.1–4.0) 6.0 (4.5–7.5)
Combined 15.8 (11.6–20.1) 10.2 (6.9–13.6) 5.6 (2.9–8.3) 6.3 (4.6–8.0)
__ denotes no estimation due to lack of original studies
Table 3 The prevalence (p) of HIV treatment failure based on HAART failure, immunological, virological, and clinical definition when
the study omitted in Ethiopia
Study omitted HAART failure P (95%CI) Immunological failure P (95%CI) Virological failure P (95%CI Clinical failure P (95% CI)
Bokretsion BG et al./2017 15.3 (10.8–19.9) 9.7 (6.3–13.2) 4.5 (2.3–6.7) 5.6 (4.2–7.1)
Yassin S /2017 15.5 (10.9–20.1) 10.5 (6.9–14.1) __ 5.5 (4.1–7.1)
Zeleke A/2016 15.6 (11.0–20.2) 10.6 (7.0–14.1) __ 6.7 (4.9–8.4)
Yimer YT/2015 15.4 (10.8–19.9) 9.8 (6.4–13.3) 6.5 (2.7–10.3) 6.3 (4.4–8.2)
Bacha T et al./2012 16.1 (10.9–21.3) 10.5 (6.6–14.4) __ 6.4 (4.3–8.4)
Ayalew MB et al./2016 17.3 (13.5–21.2) 10.8 (7.1–14.4) 6.0 (2.9–9.2) __
Sisay MM et al./2018 16.9 (12.6–21.2) 10.9 (7.7–14.1) __ 6.4 (4.4–8.4)
Tsegaye AT et al./2016 15.5 (10.9–20.1) 10.5 (6.9–14.1) __ 6.7 (5.0–8.4)
Teshome W/2015 __ 9.8 (6.3–13.2) __ __
Hailu GG et al./2015 __ 10.5 (6.9–14.1) 4.4 (2.0–6.9) __
Yayehirad AM et al./2013 __ 9.3 (6.3–12.4) __ __
Workneh N et al./2009 __ 10.1 (6.6–13.6) ___ 6.4 (4.6–8.2)
Sisay C et al./2017 15.2 (10.8–19.5) 9.8 (6.4–13.2) 6.4 (2.4–10.4) 6.5 (4.7–8.4)
Abdissa A et al./2014 __ __ 5.6 (2.7–8.6) __
Combined 15.8 (11.6–20.1) 10.2 (6.8–13.6) 5.6 (2.9–8.3) 6.3 (4.6–7.9)
__ denotes no estimation due to lack of original studies
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(AOR = 2.5; 95% CI: 1.3–4.8) to develop HIV treatment
failure as compared to their counterparts.
From a single study, male adult patients (AOR = 4.6;
95% CI: 1.7–12.3) [14], and patients in the formal educa-
tional level (AOR = 5.15; 95% CI: 1.5–17.3) [28] were at
higher risk for HIV treatment failure.
Babo YD et al/2017 (AOR = 4.9; 95% CI: 1.5–16) and
Yayehirad MA et al/2013 (AOR = 1.7; 95% CI: 1.1–2.7)
[16, 28] found that the odds of being unemployed is
more likely to develop HIV treatment failure.
Clinical-related factors
Report from one study showed that lower baseline body
mass index (BMI) (AOR= 2.8; 95% CI: 1.01–7.5) [28] and
patients who had height for age in the third percentile or less
(AHR= 3.3; 95% CI: 1.0–10.6) [22] were more likely to ex-
pose to HIV treatment failure. On the other hand, weight
change per 1 kg increase (AHR= 0.9, 95% CI: 0.9–0.9) [17],
and < 50 kg weight at baseline (AHR= 0.58, 95% CI:0.38–
0.89) [13] were less likely to expose to HIV treatment failure.
One study showed [16], being in ambulatory functional
status was at high risk (AOR = 2.9, 95%CI: 1.2–7.5) to de-
velop HIV treatment failure than being in working func-
tional status.
Another study [15] showed that those children who
did not know their HIV status were at high risk (AHR =
4.4, 95% CI: 1.8–11.3) to develop HIV treatment failure.
The pooled effects of CD4 cell count < 200 cells/mm3
(AOR = 7.2; 95% CI: 2.5–12.0), ≤ 100 cells/ mm3 (AOR =
2.1; 95% CI: 1.4–2.8) and < 50 cells/mm3 (AOR = 3.3;
95% CI: 1.4–5.3) as compared to those with > 200, > 100,
and > 50 cells/mm3 on HIV treatment failure were esti-
mated, respectively (Fig. 6).
The pooled effect of being on WHO clinical stage III/
IV found to be at higher risk (AOR = 1.9; 95% CI: 1.3–
2.6) to HIV treatment failure as compared to stage II/I.
The pooled effect of the presence of opportunistic infec-
tions (TB, diarrhea, pneumonia, other OIs) are more
likely (AOR = 1.8; 95% CI: 1.2–2.4) to expose patients to
HIV treatment failure (Fig. 7).
Drug-related factors
Stavudine based regimen (AOR = 3.5; 95% CI: 1.3–10.6)
[28], ART drug substitution (AHR = 1.7; 95% CI:1.1–2.7)
[22], substitution of original regimen (AOR = 3.3; 95%
CI = 1.6–6.7) [31], absence of PMTCT prophylaxis
(AOR = 1.4; 95% CI: 1.2–2.5) [31], and using faith heal-
ing medicine (AOR = 8.1, 95% CI: 3.1–21.5) [30] were
reported predictors of HIV treatment failure. Another
study [30] showed that patients who didn’t have consult-
ation were positively associated (AOR = 4.9,95% CI:1.5–
15.8) with HIV treatment failure.
The pooled effect (AOR) of poor HAART adherence to
HIV treatment failure was 8.1 (95% CI: 4.3–11.8) (Fig. 8).
Fig. 6 Forest plot of the adjusted odds ratios (AOR) with corresponding 95% CI of studies on the association of CD4 cells and HIV
treatment failure
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Fig. 7 Forest plot of the adjusted odds ratios (AOR) with corresponding 95% CIs of studies on the association of WHO clinical stage,
opportunistic infections, and HIV treatment failure
Fig. 8 Forest plot of the adjusted odds ratios with corresponding 95% CIs of studies on the association of poor HAART adherence and HIV
treatment failure
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Discussion
Our study has two main findings related to the national
prevalence and risk factors of HIV treatment failure. First,
we noted that using the definition of HAART failure, HIV
treatment failure was 15.9% (95% CI: 11.6–20.1%). This
finding will support the global recommendation to switch
patients on ART only after considering supplementary
treatment failure prevention activities. In a resource-
limited country, this finding could help to keep patients
longer on first-line ART regimen which preserves the
more toxic and expensive second-line ART regimen.
In Ethiopia, the threat of HIV treatment failure is be-
coming a continuing discussion. This might be due to
poor HIV care services, delayed to recognize treatment
failure, [34], late initiation of HAART [33], high burden of
opportunistic infections [35], lack of appropriate nutri-
tional support [36], ART-associated adverse reaction, [37]
and frequent psychological problem [38, 39]. Besides, the
absence of frequent therapeutic drug monitors and/ or re-
sistance testing while the patient is still on the suspect or
failing regimen. All four markers of lower socioeconomic
status (financial hardship, non-employment, rented or un-
stable housing status, and non-university education) can
be considered for the higher burden of HIV treatment fail-
ure in Ethiopia.
Though the WHO immunological criterion is a very
low sensitivity and high specificity test [40], this finding
showed that HIV treatment failure was higher (10.2%)
when the immunological definition used than that of
clinical (6.3%) and virological (5.6%) treatment failure.
This variation might be due to studies included in the
immunological definition of HIV treatment failure were
more than studies used to pool the clinical and virological
failure. Moreover, the lower prevalence of HIV treatment
failure using the clinical definition might be due to limited
diagnostic capabilities. It might be difficult to identify
treatment failure in patients under clinical monitoring
since not all HIV care clinic sites had a systematic ap-
proach and well-trained health professionals to collect
data about opportunistic infections. Therefore, using viral
load based HIV treatment failure could provide better
prognostic information about the risk of developing active
AIDS stage which will promote more effective second-line
ART. However, in most Ethiopian health institutions, viro-
logical ART failure is likely to be under-diagnosed in the
routine health system and might be limited to clinical
and/or immunological failure as a result. Although only
five studies were included to estimate virological ART fail-
ure, the third 90 target of UNAIDS seems to be achieved.
There is a plan to achieve 90% of people who are receiving
ART will have viral suppression by 2020 [8].
Based on the subgroup analysis, HIV treatment failure
is lower in children. ART monitoring using clinical and
immunological criteria is problematic in children, and
misclassification rates using the WHO pediatric guide-
lines remain high [41].
This review found that lower CD4 cell count, being on
the WHO clinical stage III/IV, presence of opportunistic
infections, and poor HAART adherence were the pre-
dominant risk factors of HIV treatment failure.
It is estimated that lower CD4 cell count and advanced
WHO clinical stage leads to HIV treatment failure. Other
studies [42, 43] reported a similar finding in other settings.
The presence of opportunistic infections, on the other
hand, linked to CD4 cell level. As patients’ immune status
becomes compromised, the rate of viral replication in-
creases. CD4 cell count is the backbone of immunity con-
struction that helps the human body to protect from the
disease and can prevent HIV replication [44].
The presence of opportunistic infection (TB, diarrhea,
pneumonia, other OIs) is more likely to exposed patients
to develop HIV treatment failure. The patient gives more
emphasis to the current problem than the chronic HIV,
as such time interruption of taking a drug, lost follow-
up, and other triple problems lead to HIV treatment
failure.
Poor HAART adherence found to have a great impact
on the occurrence of HIV treatment failure. It is widely
agreed that once treatment is initiated, it should not be
interrupted. In Ethiopia, within 07 days, nearly 11.3% of
children have poorly adhered to ART [45]. It is expected
that as duration increased the probability of ART inter-
ruptions would be more likely. The same in adult HIV
patients, treatment interruption was falingl in the range
between 11.8–25.8% [46, 47]. Acquired HIV drug resist-
ance develops when HIV mutations emerge due to viral
replication in individuals on imperfect ART adherence.
Poor ART adherence could lead to incomplete viral sup-
pression and causes HIV treatment failure. Global rec-
ommendations, like on-time pill pick-up, electronic or
paper-based appointment scheduling, SMS or telephone
call reminders, peer counseling, cognitive behavioral
therapy, and reduction of the HIV-associated stigma that
prevent missing of ART drugs are not well implemented
in Ethiopia.
Conclusions
HIV treatment failure in Ethiopia found to be high. Being
on advanced WHO clinical stage, presence of opportunis-
tic infections, and poor adherence to highly active anti-
retroviral therapy were the contributing factors of HIV
treatment failure. The current finding will have health pol-
icy and clinical implications for therapeutic management
decisions. Early identification of ART treatment failure al-
lows patients to have a higher chance of success when
switching to a second-line ART. A report on HIV treat-
ment failure will be used to monitor the progress of the
national action plan of 90–90-90 strategies.
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